Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data

BACKGROUND: Patients with polycythemia vera (PV) have a higher mortality risk compared with the general population, primarily driven by cardiovascular disease, thrombotic events (TEs), and hematologic transformations. The goal of risk-adapted therapy in PV is prevention of TEs. Current treatment rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Paranagama, Dilan, Colucci, Philomena, Evans, Kristin A., Bonafede, Machaon, Parasuraman, Shreekant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038180/
https://www.ncbi.nlm.nih.gov/pubmed/30002948
http://dx.doi.org/10.1186/s40164-018-0107-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038180/
https://www.ncbi.nlm.nih.gov/pubmed/30002948
http://dx.doi.org/10.1186/s40164-018-0107-8

Ejemplares similares